Yusof Kamisah
Overview
Explore the profile of Yusof Kamisah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
454
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamisah Y, Laher I, Syamsunarno M
Front Pharmacol
. 2025 Mar;
16:1566159.
PMID: 40028161
No abstract available.
2.
Rohmawaty E, Wiraswati H, Zahra T, Amalina S, Ramadhanti J, Rosdianto A, et al.
J Inflamm Res
. 2025 Feb;
18:2125-2136.
PMID: 39963686
Purpose: (L). Rendle has traditionally been recognized for its medicinal properties. Recent studies have suggested that its bioactive constituents possess antioxidant and anti-inflammatory properties. However, there is limited scientific evidence...
3.
Mustafa N, Siti H, Kamisah Y
Plants (Basel)
. 2025 Jan;
14(1.
PMID: 39795285
Diabetic cardiomyopathy is a significant and severe complication of diabetes that affects a large portion of the global population, with its prevalence continuing to rise. Secondary metabolites, including quercetin, have...
4.
Thangasparan S, Kamisah Y, Ugusman A, Anuar N, Ibrahim N
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769058
Cardiovascular diseases (CVD) are the number one cause of death worldwide, with atherosclerosis, which is the formation of fatty plaques in the arteries, being the most common underlying cause. The...
5.
Kamisah Y, Che Hassan H
Pharmaceuticals (Basel)
. 2024 Apr;
17(4).
PMID: 38675424
Endothelial dysfunction is a hallmark of cardiovascular diseases, contributing to impaired vasodilation, altered hemodynamics, and atherosclerosis progression. Trimetazidine, traditionally used for angina pectoris, exhibits diverse therapeutic effects on endothelial dysfunction....
6.
7.
Kamisah Y, Jalil J, Yunos N, Zainalabidin S
Plants (Basel)
. 2023 Jun;
12(11).
PMID: 37299076
Cardiac diseases, such as myocardial infarction and heart failure, have become a major clinical problem globally. The accumulating data demonstrate that bioactive compounds with antioxidant and anti-inflammatory properties have favorable...
8.
Kamisah Y, Che Hassan H
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36769115
Cardiac remodeling can cause ventricular dysfunction and progress to heart failure, a cardiovascular disease that claims many lives globally. Ivabradine, a funny channel (I) inhibitor, is used in patients with...
9.
Mustafa N, Jalil J, Saleh M, Zainalabidin S, Asmadi A, Kamisah Y
Life (Basel)
. 2023 Jan;
13(1).
PMID: 36675993
Cardiac hypertrophy is an early hallmark during the clinical course of heart failure. Therapeutic strategies aiming to alleviate cardiac hypertrophy via the mitogen-activated protein kinase (MAPK)/calcineurin-nuclear factor of activated T-cells...
10.
Ramli F, Syed Hashim S, Raman B, Mahmod M, Kamisah Y
Pharmaceuticals (Basel)
. 2022 Sep;
15(9).
PMID: 36145368
Abnormality in myocardial copper homeostasis is believed to contribute to the development of cardiomyopathy. Trientine, a copper-chelating drug used in the management of patients with Wilson's disease, demonstrates beneficial effects...